Baxter enrolls patients for late-stage study of hemophilia A drug

11/14/2013 | Pharmaceutical Business Review Online

Baxter International has enrolled all participants needed for a late-stage clinical trial of BAX 855, a candidate therapy for hemophilia A. The recombinant factor VIII was modified to have lasting effects and will be assessed for its safety and efficacy in reducing bleeding rates. The study is expected to be finished in time to support a regulatory submission late next year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA